Background
Breast cancer, a biologically and molecularly heterogeneous disease derived from epithelial cells, has been one of the most common malignancies in women worldwide for many years [
1‐
3]. As fundamental components of epithelial cells, adherent junctions (AJs) have been proven to play important roles in cancer progression [
4‐
10]. However, data on AJs in breast cancer is still scarce.
Adherens junctions-associated protein 1(AJAP1), also called Shrew-1, was initially discovered as a novel transmembrane protein of AJs in epithelial cells [
11]. Some studies then verified that AJAP1 was a promising tumor candidate gene in glioma [
12,
13], hepatocellular carcinoma [
14‐
16], esophagus carcinoma [
17] and oligodendrogliomas [
18]. However, its role in breast cancer has not been fully elucidated.
In addition, previous reports showed that 50% of breast cancer cases have Wnt signaling abnormal activation and low rates of somatic mutations [
19‐
21]. Additionally, abnormal activation of Wnt signaling often led to β-catenin nuclear accumulation [
22‐
25]. Nuclear β-catenin can function as a transcriptional co-activator of the TCF/LEF complex, resulting in a series of changes in proliferation, invasion and metastasis. Moreover, β-catenin has been implicated in the transduction of mechanical signals from junctions to the nucleus [
26].
In this study, the roles of AJAP1 and β-catenin in breast cancer were explored. Immunohistochemistry assay showed that AJAP1 depletion was positively related with β-catenin nuclear expression and poor prognosis of patients. Besides, AJAP1 was a putative tumor suppressor that suppressed the growth, migration, invasion of breast cancer and cell cycle by mediating the nuclear β-catenin activity. More importantly, β-catenin localization and tumor progression also positively fed back on EGF/EGFR-attenuated AJAP1 expression. In summary, these findings might be beneficial in developing new therapeutic targets for decreasing nuclear β-catenin-mediated malignancy in breast cancer.
Materials and methods
Patients and breast cancer samples
283 cases of paraffin-embedded breast cancer patients’ specimen and 25 pairs of fresh tumor tissues were randomly selected at Cancer Hospital of Tianjin Medical University. The patients received treatments from January 1, 2006 to December 31, 2006. None of the patients underwent chemotherapy or radiotherapy before surgery. The patient clinical pathologic features are showed in Additional file
1: Table S1. All cases had decent follow-up and reliable clinical data. Besides, this study followed the Declaration of Helsinki, and the patients provided written informed consents.
Immunohistochemistry (IHC) and evaluation
All paraffinized tissue blocks were cut at 4 μm thicknesses and detected by the SP immunochemistry kit (Zhongshan Golden Bridge Biotechnology, Beijing, China). IHC assay was conducted as previously described [
27]. The rabbit monoclonal anti-human AJAP1 antibody (Bioss, China) at 1:100 dilution or the mouse monoclonal anti-human β-catenin antibody (CTNNB1, Boster) at 1:200 dilution was used for IHC. Two senior pathologists (Yun Niu and Shuhua Lv) evaluated the score without any knowledge of the clinicopathological outcomes of the patients. The percentage of positivity of the tumor was scored as “0” (no tumor cells), “1” (1–25%), “2” (26–50%), “3” (51–75%), and “4” (> 75%). The staining intensity of the positive tumor cells was scored as “0” (no staining), “1” (weak staining), “2” (moderate staining), and “3” (strong staining). As for AJAP1, the multiplier of the scoring of (0–3) for low expression and (4–12) for high expression were used. The IHC staining results of β-catenin were evaluated independently according to the subcellular localization of the nucleus and membrane. A positive/abnormal nuclear expression was defined as over 10% of the nuclear-stained tumor cells. An abnormal membranous expression demonstrated either no immunoreactivity in the membrane or less than 10% of the cancer cells with a positive membranous staining [
28,
29].
Cell line and culture
All cell lines were purchased from the American Type Culture Collection (ATCC, USA). T47D, SK-BR-3, MCF-7 and MDA-MB-231 were cultured with the 1640 (Gibco, USA), MCF10A was cultured in DMEM-F12 (Gibco, USA) media. MDA-MB-453 was cultured in L-15 media. All media contained 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin and cell culture carried out at 37 °C in a 5% CO2 incubator.
Immunofluorescence
The cells were grown in 24 -well plates and then stimulated with 50 ng/ml EGF for 24 h. After 1 day, the cells were fixed, rehydrated, and incubated with β-catenin (Santa Cruz Biotech, China), AJAP1 (Bioss, China), and fluorescein-labeled secondary antibodies. The nuclei were stained with DAPI for 10 min. The slides were examined through a fluorescent confocal microscope.
Western blot
Cellular protein was extracted by RIPA buffer containing PMSF. The Nuclear and Cytoplasmic Isolation Kit (KeyGEN, China) was used for the cytoplasmic and nuclear protein extraction according to the manufacturer’s instructions. The proteins were separated on 10% SDS-PAGE gels, transferred onto PVDF membranes, blocked using 5% skim milk, and incubated with primary antibodies overnight at 4 °C. The protein bands were detected by the ECL detection Kit (Solarbio, China).
Plasmids and lentiviral transfection
The related siRNAs and control plasmids were showed in Additional file
2: Table S2. The viruses were packaged in 293 T cells according to the manufacturer’s instructions. The infected cells were selected with 2 μg/mL puromycin.
Quantitative reverse-transcription polymerase chain reaction (qRT- PCR) assay
Total RNAs were extracted using Trizol reagent (Takara, Japan). Reverse transcription was conducted by the SuperScript RT kit (Takara, Japan). The qRT-PCR assay was performed with SYBR Green PCR kit (Takara, Japan). Primers used are listed in Additional file
2: Table S2. GAPDH was used as the internal control. The relative expression levels were calculated by the 2
-ΔΔCt method. All experiments were assayed in triplicate.
Co-immunoprecipitation (co-IP)
The co-IP of AJAP1 and β-catenin was performed using the Pierce Co-IP kit (Thermo Scientific, USA) according to the manufacturer’s protocol as described previously [
30]. The protein quantity was then detected by western blotting.
Luciferase assays
5 × 104 cells were seeded in 24-well plates and cultured for 24 h at a density of 70–80%. The cells were transferred with 2 μg of β-catenin-responsive firefly luciferase reporter plasmid TOP-FLASH or the negative control FOP-FLASH (Merck-Millipore) using fugene6 (Invitrogen, USA) according to the manufacturer’s instructions. The cells were subjected to luciferase reporter assay 24 h after transfection according the Dual Luciferase Reporter Assay System (Promega, Madison, WI). The relative Renilla luciferase activity was normalized to that of firefly luciferase activity. Each experiment was measured in triplicate.
Migration and invasion assay
2 × 104 cells were seeded in the upper chamber with RMPI 1640 medium without FBS and a medium containing 10% FBS at 37 °C in the lower chamber. After culturing at 37 °C for 24 h, the cells in the upper chamber were harvested and then stained according to the three-step set (Thermo Scientific, USA) protocol. Scratches were made when the cells reached a 95% confluence in each well using a 10 μL plastic pipette tip. The scratches were measured and photographed. Each experiment was conducted at least three times.
2 × 103 cells were seeded in 96-well plates and the activities of the viable cells were measured at different time points using a microplate reader. In the colony formation assay, 8 × 102 cells were cultured in 6-well plates for 2 weeks. The colonies were stained with crystal violet and counted.
Subcutaneous xenograft assay
Female BALB/c nude mice (4–6 week) were injected with 5 × 10
6 treated cells and kept in the Tianjin Medical University Cancer Institute and Hospital SPF’s animal feeding center. The tumors were measured as described previously [
31]. All animals were sacrificed after 60 days. All experimental procedures were approved by the International Animal Care and Use Committee of Tianjin Medical University Cancer Institute and Hospital.
Statistical analyses
Statistical significance was determined by SPSS version 24.0. Values are shown as mean ± SD. Multiple groups were compared by one-way analysis of variance followed by Dunnett’s t-test. p < 0.05 was considered statistically significant.
Discussion
Adherens junction (AJs) are multi-protein complexes which play vital roles in many behaviors of the cell like adhesion, transfer signals for inhibition of cell growth, resistance to apoptosis and regulation of cell shape and polarity [
40‐
42]. Besides, AJs core structural component is a complex of cadherin and catenin proteins [
40]. β-catenin can bind to the cadherins in AJs. The novel molecule of AJs, AJAP1, was found to be a tumor suppressor in glioma, hepatocellular carcinoma, esophagus carcinoma, oligodendrogliomas, and cervical cancer [
12‐
14,
17,
43‐
45]. This study demonstrated that AJAP1 was a putative suppressor in breast cancer and it can interact with β-catenin in the cytoplasm and membrane. AJAP1 knocked down contributed to breast cancer malignancy through promoting accumulation of aberrant β-catenin nuclear expression, which indicated that increased expression of AJAP1 in higher grades of breast cancer could be beneficial to abrogate the β-catenin driven malignancy. Besides, the results of AJAP1 and β-catenin expression in 283 cases of breast cancer patients and overall survival further confirmed this theory.
As for β-catenin stabilization, recent researches [
32,
34,
46,
47] have revealed that the accumulation of β-catenin nuclear expression activated many oncogenes about cellular proliferation. It is noteworthy that β-catenin is an important molecule which is involved in many metastasis signals. Thus, inhibiting nuclear accumulation of β-catenin might be an effective strategy for prohibiting malignancy of tumor cells. Here, a new mechanism for β-catenin nuclear location was identified. AJAP1 depletion promoted β-catenin nuclear translocation, affected the transcription activity of β-catenin and its downstream genes like C-myc and CyclinD1 expression. Likewise, AJAP1 regulated breast cancer tumorigenesis via mediating the β-catenin activity, indicating an effective way to prevent the tumor progression.
Increasing evidence demonstrated that EGF affected the β-catenin transactivation in breast cancer [
33,
46,
48]. As expected, it was found that EGF-stimulated cells accelerated β-catenin nuclear transaction, decreased AJAP1 expression and activated the C-myc and CycliD1 expression. Previous studies revealed that EGF activated EGFR and led to the activation of downstream signaling pathways, such as PI3K/AKT and MAPK/ERK, which are critical in metastasis and tumor progression [
49‐
51]. And now EGFR mutant also occurred in breast cancer. A great deal of studies show that EGFR-target medicine made a huge breakthrough in treating cancer especially lung cancer. Above achievements inspired us to use these target medicine to treat breast cancer with high EGFR mutant rates. Besides, our results showed that EGFR had similar function on β-catenin as previously illustrated [
32,
34]. Additionally, Chao Yang et al. [
13] revealed that EGFR/EGFRvIII inhibited AJAP1 in the cytoskeleton remodel of glioma cell. However, our study explored and validated that EGFR also can inhibit AJAP1 expression and β-catenin activity in breast cancer cells. Knockdown of EGFR and AJAP1 promoted tumor growth and β-catenin nuclear expression. Collectively, EGFR acted as an important role activating β-catenin nuclear expression. These results implied that the combination of EGFR targets and AJAP1-enhanced medicine might improve the prognosis of breast cancer patients. However, further researches on different β-catenin phosphorylation spots and mutants mediated by AJAP1 need to be further conducted. Likewise, these discoveries inspire more studies to explore the role of AJAP1 in EGFR-target medicine like Gefitinib in future studies.
To the best of our knowledge, this is the first study to reveal that the aberrant nuclear localization of β-catenin in breast cancer tissues, which is associated with the expression level of AJAP1. This work clarified one new feed loop for EGF-EGFR-AJAP1-controlled nuclear location and transcription activity of β-catenin. This change affected breast cancer progression and metastasis. Given the inhibition effect of AJAP1 on breast cancer both in vivo and in vitro, new medicine targets need to be developed. Determining whether this inducer for AJAP1 has the same effect as other adherens junction-associated proteins is also significant. If so, then many new anticancer occurrences may bring new hope to breast cancer patients.
Conclusion
We reported a novel EGF/EGFR axis that negatively fed back on the AJAP1-mediated β-catenin expression pathway and it accelerated breast cancer progression. This research provided novel findings demonstrating that the combination of the inhibitor of EGFR and the AJAP1 inducer may be beneficial to breast cancer prognosis.
Acknowledgements
This study was funded by National Natural Science Foundation of China (81172532,81470119,81602340 of Shuling Wang) and the Tianjin Municipal Science and the Technology Commission Research Fund (15JCYBJC27800).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.